Knowledge Hub

Rubella (German Measles) - Pipeline Review, H2 2016

Press Release   •   Nov 30, 2016 04:50 EST has recently announced the addition of a market study “ Rubella (German Measles) - Pipeline Review, H2 2016”, is a comparative analysis of the global market.

Rubella (German Measles) - Pipeline Review, H2 2016


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rubella (German Measles) Pipeline Review, H2 2016, provides an overview of the Rubella (German Measles) (Infectious Disease) pipeline landscape.

Rubella also known as the German measles is an acute, contagious viral infection. The rubella virus is transmitted by airborne droplets when infected people sneeze or cough. Symptoms include fever, headache, stuffy or runny nose, inflamed, red eyes, aching joints and enlarged, tender lymph nodes at the base of the skull, the back of the neck and behind the ears.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rubella (German Measles) Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Rubella (German Measles) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rubella (German Measles) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rubella (German Measles) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 2, 1, 2, 1 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.Rubella (German Measles).

Rubella (German Measles) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Download The sample Copy Of This Report:


- The pipeline guide provides a snapshot of the global therapeutic landscape of Rubella (German Measles) (Infectious Disease).

- The pipeline guide reviews pipeline therapeutics for Rubella (German Measles) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Rubella (German Measles) (Infectious Disease) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Rubella (German Measles) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Rubella (German Measles) (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Rubella (German Measles) (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Rubella (German Measles) (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Content

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Rubella (German Measles) Overview 6

Therapeutics Development 7

Pipeline Products for Rubella (German Measles) - Overview 7

Pipeline Products for Rubella (German Measles) - Comparative Analysis 8

Rubella (German Measles) - Therapeutics under Development by Companies 9

Rubella (German Measles) - Therapeutics under Investigation by Universities/Institutes 10

Rubella (German Measles) - Pipeline Products Glance 11

Late Stage Products 11

Clinical Stage Products 12

Early Stage Products 13

Unknown Stage Products 14

Rubella (German Measles) - Products under Development by Companies 15

Rubella (German Measles) - Products under Investigation by Universities/Institutes 16

Rubella (German Measles) - Companies Involved in Therapeutics Development 17

Beijing Minhai Biotechnology Co., Ltd 17

Beijing Tiantan Biological Products Co., Ltd. 18

Biological E. Limited 19

Daiichi Sankyo Company, Limited 20

GlaxoSmithKline Plc 21

Indian Immunologicals Limited 22

Prometheon Pharma, LLC 23

Sinovac Biotech Ltd. 24

Zydus Cadila Healthcare Limited 25

Rubella (German Measles) - Therapeutics Assessment 26

Assessment by Monotherapy Products 26

Assessment by Combination Products 27

Assessment by Route of Administration 28

Assessment by Molecule Type 30

Drug Profiles 32

(measles + mumps + rubella + varicella) vaccine - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

(measles + mumps + rubella + varicella) vaccine - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

(measles + mumps + rubella) vaccine - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

(measles + mumps + rubella) vaccine - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

(measles + mumps + rubella) vaccine - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

(measles + rubella + varicella) vaccine - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

(measles + rubella) vaccine - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38